CT-validation of Ultrasound Based Planning for High Dose Rate (HDR) Prostate Brachytherapy Using Vitesse (Vitesse)
High Dose Rate (HDR) temporary prostate brachytherapy offers a precise form of dose escalation for prostate cancer. Needles are placed, the position is confirmed and treatment is delivered. Previously High Dose Rate prostate brachytherapy was performed under TransRectal UltraSound (TRUS) guidance but planned with Computed Tomography (CT) imaging which introduced a source of error through needle displacement while transporting and repositioning patient. Recently Varian has introduced a one-step procedure where both implant and planning are based on UltraSound imaging and performed without patient repositioning. This planning system is approved by Health Canada and is commercially available.
This study will use High Dose Rate brachytherapy to treat 15 men. Treatment will be planned with TransRectal UltraSound but validated pre-treatment using Computed Tomography imaging.
|Prostate Cancer Interstitial Radiation High Dose Rate Brachytherapy Ultrasound-based Planning Compared to CT-based Planning||Radiation: HDR prostate brachytherapy||Phase 2|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||High Dose Rate (HDR)Prostate Brachytherapy With Vitesse tm|
- Quality assessment of TransRectal Ultra-sound based plan for High Dose Rate prostate brachytherapy compared to Computed Tomography-derived plan [ Time Frame: 6 weeks ]The dosimetric quantifiers (V100: percentage of prostate volume covered by 100% prescription isodose, V150: percentage of prostate volume enclosed by 150% of prescription dose, urethral dose and rectal dose)will be used to determine differences between Ultra-sound based plan and the standard Computed Tomography-image based plan
- Accuracy of needle tip identification on TransRectal UltraSound compared to Computed Tomography [ Time Frame: 6 weeks ]Precise location of the tip of each needle in 3-dimensional space relative to the prostate determines the pattern of dose delivery. Inaccuracies in needle tip location may lead to differences detected between UltraSound-based and Computed Tomography-based plans.
|Study Start Date:||December 2010|
|Study Completion Date:||May 2012|
|Primary Completion Date:||April 2012 (Final data collection date for primary outcome measure)|
|Experimental: HDR prostate brachytherapy||
Radiation: HDR prostate brachytherapy
HDR prostate brachytherapy to be delivered in 2 fractions of 10 Gray as a "boost" combined with external beam radiotherapy
Please refer to this study by its ClinicalTrials.gov identifier: NCT01248741
|Canada, British Columbia|
|BCCA Center for the Southern Interior|
|Kelowna, British Columbia, Canada, V1Y 5L3|
|Study Director:||Matthew Schmid, MSc||British Columbia Cancer Agency Dept of Radiation Physics|